July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
A Ten-year Epidemiology of Retinopathy of Prematurity Treatment in Taiwan
Author Affiliations & Notes
  • Wei-Chi Wu
    Ophthalmology, Chang Gung Memorial Hospital, Taipei, Taiwan
  • Yu-Chuan Kang
    Ophthalmology, Chang Gung Memorial Hospital, Taipei, Taiwan
  • Shih-Ming Chu
    Pediatrics, Chang Gung Memorial Hospital, Taiwan
  • Reyin Lien
    Pediatrics, Chang Gung Memorial Hospital, Taiwan
  • Footnotes
    Commercial Relationships   Wei-Chi Wu, None; Yu-Chuan Kang, None; Shih-Ming Chu, None; Reyin Lien, None
  • Footnotes
    Support  This work was supported by Chang Gung Memorial Hospital Research Grants, Linkou, Taiwan (CMRPG3D0251-2; Taoyuan, Taiwan), and a National Science Council Research Grant (MOST 106-2314-B-182A-040-MY3; Taipei, Taiwan).
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6515. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Wei-Chi Wu, Yu-Chuan Kang, Shih-Ming Chu, Reyin Lien; A Ten-year Epidemiology of Retinopathy of Prematurity Treatment in Taiwan. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6515.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To understand the epidemiology in retinopathy of prematurity (ROP) requiring treatment in Taiwan from 2002 to 2011.

Methods : Design: A retrospective cohort study.
Setting: A referral medical center in Taiwan
Study Population: 11 180 premature patients with a length of stay > 28 days and who survived during hospitalization.
Observation Procedure: Data retrieval from the National Health Insurance Research Database.
Main Outcome Measures: Incidence of ROP treatments, including the use of laser treatment, anti-vascular endothelial growth factor (VEGF) injection, scleral buckle or pars plana vitrectomy (SB/PPV) and cryotherapy, from 2002 to 2011.

Results : Among the patients with ROP (n = 4096), 6.5% (n = 265) of them received treatment. The most frequently performed treatment was laser treatment (n = 202 [4.9%]), followed by intravitreal anti-VEGF injection (n = 49 [1.2%]), SB/PPV (n = 39 [0.95%]), and cryotherapy (n = 14 [0.34%]). The incidence of ROP requiring treatment increased during the period (P < 0.001), and so did the use of intravitreal anti-VEGF injection (P = 0.02). Shift of treatment modality from laser treatment to intravitreal anti-VEGF injection was observed. Risk factors of ROP requiring treatment included male sex (odds ratio [OR] = 1.36, P = 0.025), birth weight < 1250g (all P < 0.05), respiratory distress syndrome (OR = 1.47, P = 0.013), and patent ductus arteriosus (OR =1.55, P = 0.003).

Conclusions : In Taiwan, the incidence of use of intravitreal anti-VEGF injection for treating ROP increased between 2002 and 2010. Laser treatment was less frequently used than intravitreal anti-VEGF injection after 2010. Male sex, BW < 1250g, respiratory distress syndrome, and patent ductus arteriosus were independent risk factors of ROP requiring treatment.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.